Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report

BACKGROUND: Poly (ADP-ribose) polymerase (PARP) inhibitors are approved for the treatment of breast cancer susceptibility genes 1 and 2 (BRCA1/2) mutant ovarian and breast cancers, and are now being evaluated in metastatic castration-resistant prostate cancer (mCRPC). Reversion mutations that restor...

Descripción completa

Detalles Bibliográficos
Autores principales: Simmons, Andrew D., Nguyen, Minh, Pintus, Elias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071565/
https://www.ncbi.nlm.nih.gov/pubmed/32171277
http://dx.doi.org/10.1186/s12885-020-6657-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071565/
https://www.ncbi.nlm.nih.gov/pubmed/32171277
http://dx.doi.org/10.1186/s12885-020-6657-2

Ejemplares similares